Last checked at 
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday announced a research agreement worth USD75,000 with an undisclosed "global pharmaceutical company".
Hemogenyx is a biopharmaceutical firm developing therapies and treatments to improve bone marrow transplants in blood disease patients. It said the global company's identity "must remain confidential at their request".
Under the agreement, Hemogenyx's wholly owned Immugenyx LLC subsidiary will be paid USD75,000 by the undisclosed global company for research conducted.
Immugenyx also will grant "a worldwide, non-exclusive, royalty-free licence" to the undisclosed company covering "any know-how" as well as possible patents or patent applications stemming from the agreement. These will be used by the global company solely for research and development.
Further, Immugenyx will grant the global company "an option to an exclusive licence" to any patent or patent applications, the terms of which are to "be negotiated in good faith and on reasonable commercial terms" if the option is exercised.
This deal follows a development agreement announced in May, which covered Hemogenyx's CDX antibodies and was with the same global company.
Immungenyx also is working with Janssen Research & Development LLC - one of Johnson & Johnson's Janssen Pharmaceutical Companies.
Hemogenyx co-founder & Chief Executive Vladislav Sandler said: "This agreement represents a further step forward in the acceptance and use of our new type of humanised mice within the pharmaceutical community. We are particularly pleased to be working with this global pharmaceutical company, a leader in the field of cancer and autoimmune disease treatment.
"The agreement further affirms the value of our new type of humanised mice and lets us extend our work into a wider range of disease models and the development of specific drugs. The advancement of this research and potential future collaborations serve both as a validation of our technology and a means of support for the further development of our CDX bi-specific antibody product candidate."
Shares in Hemogenyx were up 0.5% at 2.06 pence in London on Wednesday morning.
By Anna Farley; annafarley@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
